SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Profile nucleases and Repurpose Off-Targets to Expand Gene Editing

The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.

Subsidie
€ 1.141.779
2023

Projectdetails

Introduction

Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, relies on a guide RNA (gRNA) – its program – to precisely cut a complementary genetic sequence – its target – for precision gene editing.

Applications of Programmable Nucleases

These programmable nucleases deliver cures for genetic diseases like:

  1. Anemia
  2. Blindness
  3. Cancer

They also facilitate quick disease model development and diagnostics for viruses like SARS-CoV-2.

Discovery of Nucleases

Hunts across microbial genomes have exposed thousands of programmable nucleases. Each could be another valuable tool for genome engineers, but we know just too little about them to use them safely.

Challenges with Off-Target Effects

Even Cas9 does not have guide-target parity: It cuts partially matched ‘off-target’ genome sites, which can lead to dangerous side effects. Though we work hard to avoid off-targets, partial matching may have a bright side.

Research Hypothesis

What if we leverage it, using it to make gene editing more predictable? Using high-throughput biochemistry, we will Profile nucleases and Repurpose Off-Targets to Expand Gene Editing.

The PROTÉGÉ Research Program

The PROTÉGÉ research program will:

  • Profile guide-target parity – specificity – across promising, newly discovered programmable nucleases.
  • Deliver a toolset for assessing this critical safety feature rapidly and broadly.
  • Test the hypothesis that purposefully misprogramming nucleases can direct specific repair outcomes.

Conclusion

We intend to benefit Europe and the world community with safer and more diverse gene editing tools for achieving its Horizon Europe health, technology, and environmental goals.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.141.779
Totale projectbegroting€ 1.141.779

Tijdlijn

Startdatum1-6-2023
Einddatum31-5-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VILNIAUS UNIVERSITETASpenvoerder

Land(en)

Lithuania

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.

ERC Proof of...€ 150.000
2024
Details

Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificities

EditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases.

ERC Starting...€ 1.599.500
2025
Details

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

ERC Consolid...€ 2.249.895
2022
Details

Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells

INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.

ERC Advanced...€ 2.475.491
2023
Details

Molecular mechanisms, functions and applications of RNA-guided DNA transposons

This project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine.

ERC Starting...€ 1.499.403
2024
Details
ERC Proof of...

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Starting...

Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificities

EditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases.

ERC Starting Grant
€ 1.599.500
2025
Details
ERC Consolid...

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

ERC Consolidator Grant
€ 2.249.895
2022
Details
ERC Advanced...

Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells

INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.

ERC Advanced Grant
€ 2.475.491
2023
Details
ERC Starting...

Molecular mechanisms, functions and applications of RNA-guided DNA transposons

This project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine.

ERC Starting Grant
€ 1.499.403
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder€ 4.406.097
2022
Details

Next generation gene writing platform to cure genetic and oncological diseases

Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.

EIC Accelerator€ 2.496.375
2024
Details

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder€ 2.988.377
2023
Details

FluEdit: Microfluidics Gen-editing platform voor bloedcellen

NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.

Mkb-innovati...€ 20.000
2023
Details

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

EIC Pathfinder€ 2.998.878
2025
Details
EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder
€ 4.406.097
2022
Details
EIC Accelerator

Next generation gene writing platform to cure genetic and oncological diseases

Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.

EIC Accelerator
€ 2.496.375
2024
Details
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder
€ 2.988.377
2023
Details
Mkb-innovati...

FluEdit: Microfluidics Gen-editing platform voor bloedcellen

NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2023
Details
EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

EIC Pathfinder
€ 2.998.878
2025
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.